Recombinant Human Granulocyte Colony-stimulating Factor（rhG-CSF）
- Generic Name
- Recombinant Human Granulocyte Colony-stimulating Factor（rhG-CSF）
- Indication
用于：1.各种原因引起的中性粒细胞减少证，如恶性肿瘤和白血病化疗与放疗引起的中性粒细胞减少、造血干/祖细胞移植后髓系造血功能的受抑及延迟植活鱼移植排斥；
2.周围血造血干/祖细胞移植前的干/祖细胞动员等；
3.骨髓增生异常综合征（MDS）、再生障碍性贫血伴发的中性粒细胞减少，先天性、特发性、周期性中性粒细胞减少症，但远期疗效不肯定；
4.各种严重感染，包括艾滋病及并发的感染；
5.抗艾滋病药物引起的中性粒细胞减少症也可应用。
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
- Conditions
- Multiple MyelomaHematopoietic Stem CellsLymphomaBone Marrow Transplantation
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT02682953
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
- Conditions
- AL Amyloidosis
- Interventions
- Procedure: Stem Cell CollectionProcedure: Stem cell infusion
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT02489500
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Use Art-assist and Neupogen to Treat Chronic Limb Ischemia
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT02408991
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
- Conditions
- Febrile NeutropeniaBreast CancerNeutropenia
- Interventions
- Drug: Pegylated rhG-CSF 100μg/kg
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2014-04-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 182
- Registration Number
- NCT02119715
- Locations
- 🇨🇳
307 Hospital Affiliated to Academy Military Medical Science, Beijing, China
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
- Conditions
- Breast CancerNeutropeniaFebrile Neutropenia
- Interventions
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT01611051
- Locations
- 🇨🇳
Hospital Affiliated to Academy Military Medical Science, Beijing, Beijing, China
Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)
- Conditions
- Miscellaneous Peripheral Blood Cell Abnormalities
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- Tarix Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT01543971
- Locations
- 🇺🇸
Charles River Clinical Servies Norhtwest, Tacoma, Washington, United States
Use of Granulocyte Colony-stimulating Factor for the Treatment of Recurrent Implantation Failure in IVF Patients
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 20
- Registration Number
- NCT01315470
- Locations
- 🇮🇱
Hadassah Ein Karem, Jerusalem, Israel
Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
- Conditions
- Mycoses
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT01232504
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Tandem Auto-Allo Transplant for Lymphoma
- Conditions
- Lymphoma, Low-GradeT-Cell LymphomaDiffuse, Large B-Cell, LymphomaMantle-Cell LymphomaChronic Lymphocytic LeukemiaLymphoma, Small LymphocyticHodgkin's Lymphoma
- Interventions
- Other: autologous (auto) peripheral blood stem cell transplantationOther: non-myeloablative allogeneic (allo) transplant
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT01181271
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
- Conditions
- Drug/Agent Toxicity by Tissue/OrganBrain and Central Nervous System TumorsLymphomaThrombocytopenia
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00074165
- Locations
- 🇺🇸
Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States
🇺🇸Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.